The first months of life are an important window for gut and immune development, yet many U.S. babies have low levels of beneficial Bifidobacterium, including B. infantis, the bacteria that help babies use the nutrients in human milk and support the developing immune system. 

I’ve advised two infant microbiome companies on this emerging science: reviewing research on beneficial gut bacteria and what their absence may mean (early imbalances have been linked with allergies, eczema, asthma, and obesity), and bringing a practicing pediatrician’s perspective to the research and product development behind their commercially available probiotic and synbiotic products.

The Challenge:

For a microbiome company, the science is both the opportunity and the obstacle. The research on beneficial gut bacteria is still emerging and easy to overstate. Because early imbalances have been linked with allergies, eczema, asthma, and obesity, the stakes for families are real. These companies needed more than a lab’s view of the data. They needed someone who could evaluate the research rigorously, say honestly what it does and doesn’t show, and turn it into products and education that pediatricians, lactation consultants, and parents can rely on. As a practicing pediatrician, I could connect the science to the questions families actually raise.

The Solutions I Brought:

  • Medical consulting: I brought a practicing pediatrician’s perspective to both companies’ research and product development, reviewing studies on beneficial gut bacteria and what their absence may mean for children’s health.
  • New product development: Their research programs helped inform the commercially available probiotic and synbiotic products. (Probiotics supply beneficial bacteria; synbiotics combine those bacteria with nutrients, like human milk oligosaccharides, that help them grow and work.)
  • Clinical research: I’ve worked on clinical studies and continue to help plan further research into safety and efficacy in U.S. babies.
  • Medical education: I support medical outreach and consumer education, including on social media, explaining the evidence behind specific products, what studies have shown, and which questions still need answers for pediatricians, lactation consultants, other clinicians, and parents.

The Results:

  • Research programs informed the development of commercially available infant probiotic and synbiotic products
  • Clinical studies completed and additional U.S. research in planning
  • Science translated into clear education for clinicians and parents, increasing brand awareness and trust
Scroll to Top